UroCor to distribute radiation seed implants:
This article was originally published in Clinica
Executive Summary
UroCor has signed an exclusive five-year marketing agreement with Mills Biopharmaceuticals for its Iodine 125 radiation seed implants for use in brachytherapy. Under the agreement, the two companies will share revenues resulting from Oklahoma City-based UroCor's direct sales in the US and from any other distribution agreements it forms. Mills has filed for approval in the US for the product. Iodine 125 seeds are used to treat prostate cancer, which affects about 200,000 men annually.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.